Legal & General Group Plc Purchases 288,691 Shares of The Chemours Company $CC

Legal & General Group Plc increased its stake in The Chemours Company by 19.7% in Q2, purchasing 288,691 shares. Analysts have mixed ratings on Chemours, with a consensus "Hold" and an average target price of $17.50. Chemours reported Q3 earnings of $0.20 per share, missing estimates, and announced a quarterly dividend of $0.0875. The stock opened at $12.79, with a market cap of $1.92 billion.

Legal & General Group Plc raised its position in shares of The Chemours Company (NYSE:CC - Free Report) by 19.7% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,752,901 shares of the specialty chemicals company's stock after purchasing an additional 288,691 shares during the quarter. Legal & General Group Plc owned 1.17% of Chemours worth $20,071,000 as of its most recent SEC filing.

3 Energy Giants Amp Up Dividends—Here’s What It Means for Investors

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. MTM Investment Management LLC purchased a new position in shares of Chemours in the second quarter worth approximately $27,000. SouthState Corp purchased a new position in shares of Chemours during the 1st quarter worth $34,000. GAMMA Investing LLC increased its stake in shares of Chemours by 130.7% in the 2nd quarter. GAMMA Investing LLC now owns 3,175 shares of the specialty chemicals company's stock worth $36,000 after purchasing an additional 1,799 shares in the last quarter. FNY Investment Advisers LLC increased its stake in shares of Chemours by 100.0% in the 2nd quarter. FNY Investment Advisers LLC now owns 4,000 shares of the specialty chemicals company's stock worth $45,000 after purchasing an additional 2,000 shares in the last quarter. Finally, CWM LLC raised its holdings in Chemours by 34.7% in the 2nd quarter. CWM LLC now owns 4,290 shares of the specialty chemicals company's stock worth $49,000 after purchasing an additional 1,104 shares during the period. Hedge funds and other institutional investors own 76.26% of the company's stock.

Wall Street Analysts Forecast Growth

CC has been the subject of several recent research reports. UBS Group cut their price target on Chemours from $21.00 to $18.00 and set a "buy" rating for the company in a report on Tuesday, November 11th. Royal Bank Of Canada reduced their target price on shares of Chemours from $19.00 to $17.00 and set an "outperform" rating for the company in a report on Monday, November 10th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Chemours in a report on Wednesday, October 8th. Mizuho dropped their price target on shares of Chemours from $19.00 to $18.00 and set an "outperform" rating for the company in a research report on Thursday, October 16th. Finally, Truist Financial decreased their price objective on shares of Chemours from $21.00 to $18.00 and set a "buy" rating on the stock in a research report on Monday, November 10th. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $17.50.

Nuclear Stocks Are Melting Down—Should Investors Panic?

View Our Latest Report on CC

Chemours Price Performance

CC stock opened at $12.79 on Friday. The Chemours Company has a one year low of $9.13 and a one year high of $22.26. The company's fifty day moving average price is $13.54 and its 200-day moving average price is $13.21. The company has a debt-to-equity ratio of 13.66, a quick ratio of 0.88 and a current ratio of 1.71. The company has a market capitalization of $1.92 billion, a PE ratio of -5.76 and a beta of 1.64.

3 Alternative Energy ETFs That Are Crushing the Market This Year

Chemours (NYSE:CC - Get Free Report) last posted its earnings results on Thursday, November 6th. The specialty chemicals company reported $0.20 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.04). The company had revenue of $1.50 billion for the quarter, compared to analysts' expectations of $1.50 billion. Chemours had a negative net margin of 5.70% and a positive return on equity of 35.27%. The business's revenue was down .9% on a year-over-year basis. During the same period in the previous year, the business posted $0.40 earnings per share. Chemours has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities analysts anticipate that The Chemours Company will post 2.03 EPS for the current fiscal year.

Chemours Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 15th. Investors of record on Friday, November 14th will be given a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Friday, November 14th. Chemours's payout ratio is currently -15.77%.

Chemours Profile

(Free Report)

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

Should You Invest $1,000 in Chemours Right Now?

Before you consider Chemours, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.

While Chemours currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here